Search

Your search keyword '"Habib, Ali A."' showing total 126 results

Search Constraints

Start Over You searched for: Author "Habib, Ali A." Remove constraint Author: "Habib, Ali A." Database Unpaywall Remove constraint Database: Unpaywall
126 results on '"Habib, Ali A."'

Search Results

4. Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010)

5. Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001)

6. Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis (P10-11.005)

7. Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-label Extension Studies (P10-11.003)

8. LUMINESCE, a Phase 3 Study of Satralizumab in Generalized Myasthenia Gravis (gMG): Baseline Characteristics (P10-11.015)

9. Treatment Fluctuations in Patients with Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis on Maintenance Ravulizumab Treatment (P10-11.001)

10. The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004) (P4-14.017)

14. Hospitalizations and Mortality From Myasthenia Gravis

15. Rozanolixizumab responder and minimal symptom expression rates in generalized myasthenia gravis: Pooled phase 3 and extension studies

19. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial

25. 2634 Cyclical rozanolixizumab treatment in generalised myasthenia gravis (gMG): pooled analysis of MycarinG (Phase 3 study) and two open-label extension studies

27. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

30. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs

32. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

33. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

36. Long-term Efficacy and Safety of Symptom-driven Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Pooled Analysis of a Phase 3 Study and Two Open-label Extension Studies (P1-5.012)

39. Efficacy of Rozanolixizumab in Generalized Myasthenia Gravis: Subgroup Analyses from the Randomized Phase 3 MycarinG Study (S5.007)

43. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

44. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial

45. Outcomes After Percutaneous Tracheostomy in Patients with COVID-19: A Single-Center Series of 377 Cases

49. Patient preference for virtual versus in‐person visits in neuromuscular clinical practice

50. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Catalog

Books, media, physical & digital resources